Introduction
Glomerulosclerosis is characterized by sclerosis or scar formation of the capillary tuft of glomeruli. Focal segmental glomerulosclerosis (FSGS), the primary glomerular disease caused by glomerulosclerosis, brings about heavy proteinuria and renal insufficiency. 1 The proposed pathogenesis of glomerulosclerosis is podocyte injury or glomerular hyperfiltration by insufficient amounts of nephrons. Although the mechanism underlying the disease progression remains unanswered, the activity of interstitial infiltrating lymphocytes is strongly suspected for disease progression. 2 Large amounts of proteins that are leaked from injured glomeruli are reabsorbed by the proximal tubular epithelium. The proteins are modified in lysosomes, which then attain a chemotactic function for circulating lymphocytes and macrophages. 3 The cytokines released by these recruited inflammatory cells can damage both the tubular epithelial cells and surrounding vessels. This damage, in turn, disconnects linkages to glomeruli and makes them isolated. Repeated cycles of this type of damage are responsible for further deterioration by glomerulosclerosis and worsening renal functions. [4] [5] [6] Current therapeutic methods are not satisfactory because long-term exposure to conventional drugs induces side effects to several organs. Further, the drugs are not necessarily interrupting or reversing progression of the disease, and thus kidney dialysis or transplantation is required to manage end-stage renal failure. Modification of an inflammatory response in affected glomeruli could attenuate the pathological consequences of kidney failure as inflammation is a salient feature of the disease and as the disease has a convincing immunologic background. Therefore, it seems reasonable to prevent kidney failure by bolstering anti-inflammatory mediators, using anti-inflammatory cytokines, or blocking the production of proinflammatory mediators. 7, 8 IL-10, originally termed cytokine synthesis inhibitory factor, is a 35 kDa homodimeric cytokine that is produced by macrophages, Type 2 Helper T (Th2) cells and B cells. 9 IL-10 participates mainly in immunesuppressive roles, which are mediated through the inhibition of proinflammatory cytokines produced by Th1 cells 10 and the downregulation of antigen presentation by dendritic cells and macrophages. 11, 12 The experimental animal models of nephritis can be induced by antiglomerular basement-membrane antibodies, high-protein diets, chemical reagents such as puromycin, unilateral ureteric obstruction, etc. [13] [14] [15] [16] [17] [18] [19] However, all these models suffer from abrupt metabolic or mechanical alterations that do not necessarily occur naturally. In the FGS/Kist mouse strain, FSGS develops spontaneously, and eventually progresses into kidney failure with nephritis. FGS/Kist mice have been characterized as having high proteinuria, renal lesions with focal sclerosis of glomeruli, and tubular atrophy with interstitial nephritis in the kidney. These characteristics resembles human disease. 20 Both, FSGS and proteinuria develop about 6 weeks after birth of the mice, and kidney failure occurs within 1 year.
This study examined whether adenovirus-mediated IL-10 gene transfer would help attenuate glomerulosclerosis in FGS/Kist mice. Our results show that human IL-10 expression in the kidney can block the development of glomerulosclerosis and proteinuria, which are the critical disease manifestations leading to renal failure.
Results

Efficient transduction of recombinant adenoviruses in renal tissue
To examine transduction efficiency of recombinant adenoviruses in the kidney, Ad:LacZ was injected into the kidney. Transduction efficiency was determined by the X-gal staining of kidney sections embedded with paraffin. In total, 20 ml of Ad:LacZ (5 Â 10 9 plaque forming units (PFU)/ml) were injected into the parenchyma of the left kidney that was exposed by a flank incision of the mice. In all, 24 h after the injection of Ad:LacZ into the kidney, both the right and the left kidneys were harvested, and stained in X-gal solution. The viral injection resulted in significant transduction of both the cortex and medulla of the left kidney compared to the kidney of sham control mice (Figure 1a and b) . Interestingly, b-galactosidase activity was also detected in the contralateral (right) kidney, although with much less X-gal staining than that of the injected kidney ( Figure 1c ). X-gal staining was detected in the cortex, but not in the medulla of the contralateral kidney. Microscopic examination of sections of the left kidney exhibited X-gal staining in Bowman's capsular epithelia as well as tubular epithelia, without global staining of glomeruli (Figure 1e ). These results indicate that after parenchymal injection, recombinant adenoviruses can efficiently transduce some types of renal cells, but not all cell types.
We then examined the levels of LacZ expression on days 1, 3 and 5 in both the left and the right kidneys. LacZ expression in the left kidney was 204.0 mU724.0 per mg protein on day 1, 18.1 mU72.5 on day 3, and 2.3 mU70.6 on day 5 (Figure 2a ). LacZ expression was also detected in the contralateral kidney, and was 131.9 mU723.0 per mg protein on day 1, and 9.2 mU73.4 on day 3. LacZ expression was also examined in other tissues of the transduced mice to detect the leakage of locally injected viruses. After 5 days, LacZ expression was not detected in the heart or lung, but a relatively high level of LacZ expression was found in the liver (168.5 mU729.0 per mg protein on day 1). LacZ expression was also detected in the spleen for 3 days (77.5 mU714.0 per mg protein on day 1) (Figure 2b ).
When LacZ expression in various tissues was examined following the intravenous (i.v.) injection of Ad:LacZ, LacZ expression was not detected in the kidney. By contrast, the liver and the spleen exhibited high levels of LacZ expression. In both experimental groups, peak expression was seen on day 1 in the spleen and on day 5 in the liver (Figure 2c ). 9 PFU/ml). After killing the transduced mice, the kidneys were fixed by glutaraldehyde perfusion and incubated in X-gal solution (1.5 mM potassium ferricyanide, 1.5 mM potassium ferrocyanide and 1% X-gal) for 4 h and then examined under a microscope (a-c). The kidneys were also examined for b-galactosidase expression by histochemical analysis of paraffin sections. Sections of 4 mm thickness were counterstained with eosin and hematoxylin (d and e). To confirm human IL-10, production in mice, ELISA was performed after transduction using sera, kidney, liver and spleen. Sera and each organ from mice transduced with 20 ml of Ad:hIL-10 (5 Â 10 9 PFU/ml) were harvested on days 1, 5, 10, 15 and 20 after the parenchymal injection. IL-10 levels in the kidney peaked biphasically on days 5 and 15 and was elevated over 20 days (Table 1) . IL-10 was detected in the liver in a similar biphasic manner, although at slightly lower levels than found in the kidney. By contrast, the peak level of IL-10 in the spleen occurred on day 5 and decreased gradually.
Similarly, the serum level of IL-10 peaked on day 5 and declined rapidly afterward. IL-10 was also detected for 15 days in contralateral kidneys as expected from the observation of LacZ expression in the contralateral kidney.
Inhibition of FSGS by Ad:hIL-10 transduction
In the FGS/Kist mouse strain, there is a spontaneous development of glomerular damage, which is characterized by FSGS. Proteinuria is also detected in the mice from 6 weeks of age. At the age of 6 weeks, glomerular sclerotic indexes of males and females were 0.0570.03 and 0.0670.06, respectively. Glomerular sclerotic indexes at the age of 10 weeks increased to 0.6970.32 and 0.1270.08 in male and female mice, respectively ( Table  2 ). The increase in the sclerotic index was more pronounced in male mice, but was still significantly increased in female mice. This pattern was consistent with the natural development of glomerular damage in this type of mouse. 
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In FSGS, the infiltration of inflammatory cells and subsequent tissue inflammation play a key role in disease progression. As IL-10 is a potent immunosuppressive cytokine, exogenous IL-10 could be effective in the inhibition of FSGS progression. Ad:hIL-10 was found to transduce the kidney efficiently, and IL-10 was expressed at a high level as shown above, although the expression was transient because of the immunogenic nature of adenoviral vectors.
We then analyzed the efficacy of IL-10 in the inhibition of glomerulosclerosis in the kidney of FGS/Kist mice. The mice were transduced with Ad:hIL-10 or Ad:LacZ at 1 Â 10 8 PFU in the left kidney at the age of 6 weeks. FSG/Kist mice do not show detectable histological damage of glomeruli and tubules of the kidney at 6 weeks. However, by the age of 10 weeks, the mice exhibit tubular atrophy, the infiltration of inflammatory cells, and the interstitial fibrosis of the kidney. By 10 weeks, kidney abnormalities affect 20% of the kidney cortex.
When mice were transduced with Ad:hIL-10, they were shown to have significantly reduced glomerulosclerosis. The glomerular sclerotic index was 0.0170.02 (Po0.001) in male mice and was almost zero (Po0.01) in female mice (Table 2 ). Inflammatory cells were not detected in the kidney of either male or female mice transduced with Ad:hIL-10. By contrast, mice treated with Ad:LacZ had severe glomerulosclerosis and heavy infiltration of inflammatory cells in the kidney (Figure 4 ).
Reduction of proteinuria by Ad:hIL-10 transduction
Mice with FSGS often reveal excessive secretion of proteins in urine because of the compromised filtration and/or reabsorption of proteins in glomeruli and in collecting tubules of the kidney. Therefore, we examined whether IL-10 expression in the kidney can also alleviate proteinuria. The naive group was shown to start proteinuria at about 6 weeks of age, and severe proteinuria was observed at 10 weeks. Whereas the Ad:LacZ-transduced group had a severity level of 3+ in six of 12 mice (50%), the mice transduced with Ad:hIL-10 exhibited significantly reduced levels of proteinuria (severity 0 or 1+) at 10 weeks (Table 3) . These results indicate that IL-10 can effectively inhibit the progression of both FSGS and proteinuria in FGS/ Kist mice.
suppression of TGF-b1 expression by Ad:hIL-10 transduction TGF-b1 promotes the synthesis of extracellular matrix (ECM) proteins, leading to a thickening of basement membranes and subsequent glomerulosclerosis. Therefore, we examined whether Ad:hIL-10 reduces TGF-b1 mRNA as well as its proteins in the kidney of FGS/Kist mice.
Kidneys were obtained from six mice in each group at 10 weeks. Quantification of TGF-b1 mRNA showed that the kidneys treated with Ad:hIL-10 significantly reduced TGF-b1 mRNA (10.2-fold decrease compared with the naive control at 10 weeks; Po0.01). This was also the case in contralateral kidneys (six-fold decrease compared with the naive control at 10 weeks; Po0.01) ( Figure 5 ). Immunohistochemistry was carried out to determine whether TGF-b1 expression was reduced by Ad:hIL-10 transduction. Immunostaining of TGF-b1 in the kidneys of Ad:hIL-10-treated mice was found to be significantly a Six mice from each group were transduced with 10 8 PFU of Ad:hIL-10 or Ad:LacZ at the age of 6 weeks. The mice were killed at 6 weeks (naive control I) or at 10 weeks (naive control II, Ad:LacZ, and Ad:hIL-10). The glomerular sclerotic index was scored. Values shown represent the mean7s.d. values of kidneys from six mice after viral transduction. The glomerular sclerotic scores evaluated the severity of the damage and were in a range from 0 to 2+ (0, normal glomerulus; 1+, sclerosis involving less than 50% of a glomerular tuft area; 2+, sclerosis involving more than 50% of a glomerular tuft area). The glomerular sclerotic index was calculated as follows: sclerotic index=[(n0 Â 0)+(n1 Â 1)+(n2 Â 2)]/ total glomeruli counted. A minimum of 50 glomeruli was randomly assessed to determine the sclerotic index for each animal. * Po0.001 in the male group treated with Ad:hIL-10 versus male control II. 
Discussion
Glomerulosclerosis is associated with the infiltration of circulating inflammatory cells, interstitial fibrosis and tubular atrophy, and is shown in patients with advanced nephritis. Glomerular injury caused by several factors brings about proteinuria in which proteins bind with soluble immunoglobulins (sIgA, sIgG and sIgM), forming immune complexes on the basement membrane. These immune complexes function as a chemotatic factor for inflammatory lymphocytes, which cause excessive immune responses in affected areas. 6 When tubules are damaged by inflammatory cells, blood vessels connected with glomeruli are also injured and occluded. As a consequence, glomeruli become damaged and deteriorate. These glomerular changes are followed by tubulointerstitial fibrosis, which progresses into eventual renal failure. [21] [22] [23] Cytokines such as IL-1, tumor necrosis factor-a (TNFa) and substances derived from platelets have a role in augmenting neutrophil-mediated glomerular damages. 24 Through the release of inflammatory cytokines, macrophages may also stimulate mesangial cells to proliferate and synthesize ECM proteins. The accumulation of ECMs such as collagen and a-smooth muscle actin is critically related to renal injury, and is induced by cytokines such as TGF-b, platelet-derived growth factor (PDGF), endothelin and angiotensin II. 25 These findings suggest that reduction of the disease mediators could be an effective means for preventing glomerular damage. To attenuate the pathological consequences of inflammatory responses in the glomerulus, the exogenous introduction of anti-inflammatory cytokines or blocking the production of proinflammatory cytokines could be beneficial, and this approach has been attempted for some inflammatory diseases. [29] [30] [31] [32] In this study, the mice with exogeneous IL-10 expression were found to have a significant reduction of the glomerular sclerotic index at 10 weeks when compared with LacZ-treated or naive controls. These results indicate that immunosuppression by IL-10 expression in the kidney can prevent the onset of glomerulosclerosis. These observations may explain why immune activation by infiltrated lymphocytes in the tubulointerstitial area plays an important role in the development of glomerulosclerosis in FGS/Kist mice.
Besides the X-gal staining of the treated left kidney, staining was also consistently found in the cortex of the contralateral right kidney, although gene expression was much lower than in the left kidney. This phenomenon may be explained by the cellular trafficking of transduced cells via lymph nodes as suggested in an earlier report, or by circulating adenoviral vectors leaked by the tissue damage inflicted during intraparenchymal injection. 33 However, the leakage of adenoviral vector appears less likely in that i.v. injection of the vector did not result in any significant viral transduction in the kidney (data not shown). Previously, the tubular uptake of FITColigonucleotides complexed with HVJ liposomes was similarily reported in the contralateral right kidney. 34 Meanwhile, intense uptake of HVJ liposome complexes by glomeruli was detected in the left kidney with arterial infusion. Ad:hIL-10 transduction was also performed in the left kidney leaving the right kidney as a control, but we observed a similar therapeutic effect in the right kidney. This was expected because IL-10 expression was detected in the contralateral kidney of the treated mice as was also shown with b-galactosidase expression. Transgene expression in the contralateral kidney suggests the potential utility of systemic vector transduction for the IL-10-mediated treatment of FSGS. However, it is believed that the therapeutic effect of exogenous IL-10 in the kidney was obtained by high levels of local (microenvironment to be more precise) IL-10 concentration. Our data support this interpretation in the following ways. Firstly, i.v. injection did not result in significant therapeutic effect in the kidney, probably because of low levels of IL-10 present in the local environment of the kidney. Secondly, IL-10 concentration in the serum plasma after i.v. injection was similar to that obtained after parenchymal injection. This may be explained by the rapid initial clearance of the viral vectors during circulation. Thirdly, after viral vector injection via i.v., most of the viral transduction (observed by b-galactosidase expression) was found in the liver and spleen; little transduction was found in the kidney. In fact, we observed hardly any viral transduction in the kidney.
Examination of reporter-gene expression in FGS/Kist mice showed that LacZ expression in the left kidney was highest 24 h post-transduction and decreased to a base level in 5 days. Transgene expression in the kidney was found to last longer with IL-10 when compared with LacZ. That IL-10 is a potent immune-suppressive 
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Y-K Choi et al cytokine explains the prolonged expression of IL-10. The rather short duration of X-gal staining in the transduced tissue can be explained mainly by host immune responses to adenoviral vector as claimed by previous reports. [35] [36] [37] Also, it may be in part because of the LacZ protein itself, and damage of renal tissue by the parenchymal injection. 38, 39 Biphasic transgene expression was observed after the transduction of recombinant adenovirus. Biphasic gene expression was also reported after the intradermal injection of pIL-12. 40 It was shown that the enhancement of gene expression could be detected after activation of the CMV promoter by proinflammatory cytokines. Gene expression mediated by the CMV promoter was found to be repeated in recurrent inflammatory conditions. 41 Thus, biphasic gene expression may be explained by the proinflammatory conditions brought on by immune responses to cells transduced by recombinant adenoviruses.
Whereas parenchymal injection resulted in transgene expression in tubular and Bowman's capsular epithelial cells, transgene expression was not detected in glomeruli in our study. It has been reported that localized transgene expression is detected by employing various vectors. Various viral or nonviral vectors were injected into renal cells through different routes, via intra-arterial, intraureteral or intraparenchymal injections. It appears that vector tropism and delivery routes determine the cell types or localized areas for viral transduction or nonviral transfection. The b-galactosidase-positive cells were observed in proximal tubule cells when the adenoviral vector was selectively perfused via the renal artery, while tubule cells from the papilla and medulla were selectively transduced by retrograde infusion. 42 bgalactosidase-positive cells were seen in cortical interstitial tissues upon renal arterial infusion by the following manuplations: (1) the use of cold incubation to prolong transduction time of the adenovirus while limiting ischemic injury, and (2) the use of vasodilators. 43 In other reports, glomerular endothelial cells were found to be efficiently transduced by the continuous reperfusion of a recombinant adenovirus into the renal artery. 44, 45 These reports as well as our results demonstrate that different delivery routes and methods result in transgene expression in different cell types and/or areas of the kidney.
We observed clear therapeutic effects in the kidney of FGS/Kist mice, even if transgene expression was largely limited to tubular and Bowman's capsular epithelial cells. Although, renal dysfunction is initiated with FSGS in FGS/Kist mice, progression of the disease is accompanied by secondary immune responses that occur after minimal changes in the glomeruli. Since tubular epithelial cells produce inflammatory cytokines, blockade of the immune responses mediated by the cytokines can be of help in the prevention of infiltration of inflammatory cells in tubulointerstitial areas.
Presently, alleviation of proteinuria and inflammatory conditions using immunosuppressive drugs such as steroids and cyclosporin are the methods for treating nephritis. However, long-term exposure to these drugs induces side effects in several organs. Local administration of IL-10 that lasts for a prolonged period of time may be a logical approach for the prevention or the blockade of disease progression of inflammatory renal diseases. It would be useful to determine if exogenous expression of IL-10 could have a similar effect in other animal models of glomerular diseases as well as in humans.
Materials and methods
Cell lines and animals
Totally, 293 cells (Microbix, Toronto, Ontario, Canada) were cultured in DMEM medium containing 10% heatinactivated calf serum (JBI, Daegu, Korea), penicillin (100 U/ml) and streptomycin (100 m/ml) in a humidified, 5% CO 2 incubator at 371C. Male and female FGS/Kist mice were supplied by the Korea Research Institute of Bioscience and Biotechnology (KRIBB, Daejeon, Korea). Water and food were provided ad libitum. After adaptation for 1 week, mice were used for experiments.
Construction of an adenoviral shuttle vector (pAd-YC2) pDE1sp1A (Microbix) was digested with BglII, and HindIII. The cytomegalovirus (CMV) promoter was also generated from the digestion of pRC/CMV (Invitrogen, Carlsbad, CA, USA) with BglII and HindIII. The CMV promoter was ligated into pDE1sp1A, resulting in an adenoviral shuttle vector with the CMV promoter and multiple cloning sites, which was termed pAd-YC. The pAd-YC was cut with ClaI and blunted to accommodate a synthetic linker with several restriction sites, BamHI, ClaI, NheI and ApaI as well as the bovine growth hormone polyadenylation signal sequence [bGHp(A)]. bGHp(A) was derived from the pRC/CMV vector after digestion with ApaI and PvuII. The pAd-YC, the synthetic linker and bGHp(A) were triple ligated to form another shuttle vector, pAd-YC2.
Recombinant Ad vectors
The type 5 adenoviral vector, which was replication defective with the E1 deletion was constructed to encode the human IL-10 cDNA under the control of the CMV promoter and contained the bGHp(A) sequence. We also constructed a type 5 adenoviral vector harboring the bgalactosidase gene (Ad:LacZ) to examine transduction efficiency and as a control. For homologous recombination, a shuttle vector, pAd-YC2, and a rescue vector, pJM17, 46, 47 were co-transfected into 293 cells with Tfx20t (Promega, Madison, WI, USA) according to the manufacturer's protocol. In all, 293 cells were plated 24 h prior to transfection at 70% confluency in a 24-well plate. Totally, 30 ml of Tfx-20, 4 mg of the shuttle vector, and 6 mg of pJM17 were used for each plate. After the transfection, cells were fed with fresh DMEM every 3 days until the onset of the cytopathic effect (CPE). To purify pure plaques, cell culture supernatant was serially diluted in serum-free media and incubated with 293 cells at 371C for 1 h. An equal volume mixture of 2 Â medium and 1% agarose was overlayed on 293 cells. After 7 days, plaques that were well isolated were further purified and propagated in 293 cells and screened by PCR using upstream primers derived from the CMV promoter and downstream primers from the bGHp(A) sequence. Viruses containing the human IL-10 cDNA or the LacZ gene were then amplified and purified with a cesium chloride density gradient. Viral titer was determined by agarose overlay. After the CsCl purification, purified
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In vivo administration of recombinant Ad vectors
FGS/Kist mice at the age of 6 weeks were anesthetized with ketamine (70 mg/kg) and xylazine (7 mg/kg) by intraperitoneal injections. The left kidney was exposed via a flank incision and injected into the parenchyma with 20 ml of Ad:hIL-10 (5 Â 10 9 PFU/ml) or 20 ml of Ad:LacZ (5 Â 10 9 PFU/ml) using a 26-guage Hamilton syringe (Hamilton, Reno, NV, USA).
In situ RT-PCR to detect IL-10 transcript
Mice transduced with Ad:hIL-10 were killed one day after the parenchymal injection. Cryostat sections of the perfusion-fixed kidney were cut to 10 mm thickness and mounted on Poly-Prep TM (Sigma, St Louis, MO, USA) slides with Tissue-Tek TM OCT compound (Miles, Elkhart, IN, USA). The OCT compound was removed with DEPC-PBS. Sections were delipidated with graded ethanol washes, rehydrated, and permeabilized in 0.1% Triton X-100 for 90 s. The detergent was washed with DEPC-PBS, and the tissue was incubated with 20 ml of proteinase K (1 mg/ml) solution for 10 min and inactivated for 5 min at 951C. Then, 5 U of RNase-free DNase I (Promega) were added to the tissue, and the tissue was incubated at 371C overnight. The next day, slides were incubated at 751C to inactivate DNase I activity and were washed with DEPC-PBS. RT-PCR was carried out in 5 Â reaction buffer (Promega) with 10 Â DIG labeling Mix (Roche Molecular Biochemicals, Mannheim, Germany), 5 U of AMV reverse transcriptase, 5 U of Tfl polymerase, and 1 mM of MgSO 4 . Primers were derived from the coding region of human IL-10 cDNA (upstream primer: 5 0 -CAT GCA CAG CTC AGC ACT GCT C-3 0 , downstream primer: 5 0 -GTC GCC ACC CTG ATG TC-3 0 ). The tissue sections were then washed successively in 2 Â SSC, 1 Â SSC, and 0.5 Â SSC for 10 min each. The sections were blocked in 100 mM maleic acid and 150 mM NaCl containing 1% bovine serum albumen (BSA) and 5% calf serum for 30 min. The slides were incubated for 1 h at room temperature with anti-dig antibody conjugated with alkaline phosphatase (Roche Molecular Biochemicals), which was diluted 1000-fold with 0.1% BSA solution. Tissues were then incubated with NBT/BCIP (Sigma) for 10 min and the reaction was stopped with 0.5 M EDTA. The tissues were dehydrated and mounted with synthetic mountant (Shandon Inc., Pittsburgh, PA, USA) for observation.
Evalution of gene expression
One day after the intraparenchymal injection of Ad:LacZ, the FGS/Kist mice were killed. The kidneys were harvested and examined for b-galactosidase expression by employing both LacZ staining and colorimetric assay. After the dissection of individual kidneys, kidney sections were fixed with 0.05% glutaraldehyde in PBS by perfusion for 15 min, and incubated in X-gal solution (1.5 mM potassium ferricyanide, 1.5 mM potassium ferrocyanide, and 1% X-gal) at 371C for 4 h. The kidney sections were then embedded with paraffin. Tissue sections of 4 mm were counterstained with eosin and hematoxylin. Colorimetric assay for b-galactosidase expression was performed as follows: whole kidney tissue was homogenized in ice-cold 0.25 M Tris-HCl (pH 8.0) on days 1, 3, 5 and 10 after transductions. The homogenate was subjected to freezing and thawing 3 times, and was centrifuged at 3000 rpm for 5 min. The cell lysates, 30 ml, were incubated with 150 ml of 2 Â bgalactosidase buffer (200 mM sodium phosphate, pH 7.3, 2 mM MgCl 2 , 100 mM b-mercaptoethanol, and 1.33 mg/ ml ONPG) for 2 h at 371C. The reaction was stopped by adding 500 ml of 1 M sodium carbonate. b-Galactosidase activity in the extract was measured for OD. at 420 nm and normalized for a total protein content. The protein content was measured with a protein assay kit (Bio-Rad, Hercules, CA, USA). The assay was calibrated with a standard curve that was generated by using purified bgalactosidase. Gene expression in the kidney was shown as cellular b-galactosidase activity per mg protein.
Measurement of IL-10
Serum and homogenated tissue of the kidney, the liver and the spleen were harvested on days 1, 5, 10, 15 and 20, and stored at À701C until tested. Tissues were homogenized and incubated at 41C in cell lysis buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 0.6% octylphenoxy-polyethoxy-ethanol (Nonidet P-40). 48 Homogenates were then sonicated and centrifuged at 12 000 rpm for 10 min at 41C. IL-10 concentration in serum and tissue homogenate was quantificated using an enzymelinked immunosorbent assay (ELISA) kit (BioSource International, Camarillo, CA, USA). In brief, 96-well plates coated with antibodies specific for IL-10 were incubated with serum samples or standards for 3 h at 371C. Plates were washed, and biotinylated anti-IL-10 antibodies were added into each well. After 1 h incubation at room temperature, plates were washed and incubated with streptavidin-horseradish peroxidase conjugates for 1 h at room temperature. After washing, enzyme activity was determined by adding 2, 2-azinobis-(3-ethybenzthiazoline-6-sulfonic acid) and measured for optical density at 405 nm in a microplate reader. The means of duplicated wells were subtracted from the means of controls, and IL-10 concentrations were calculated using a standard curve.
Proteinuria assay
Urine samples from FGS/Kist mice transduced with Adh:IL-10 and Ad:LacZ as well as from naive controls were collected 4 weeks after transductions. Urine was individually collected from 12 mice (male¼6, female¼6) from each group using micropipettes once a day. Proteinuria was measured with a Lab-stix kit (New England Medical Supply, Providence, RI, USA). Grading was done on a scale from 0 to 3+.
Histological analysis
Kidney tissue was fixed in 10% buffered-formalin, embedded in paraffin, cut to 4 mm thickness, and was stained with periodic acid-Schiff (PAS) reagent. Histological evaluations were made by two independent expert observers without prior knowledge of the experimental design. The glomerular sclerosis index was modified to simplify the scoring of glomerular scarring, which was previously described by Saito et al. 49 The glomerular sclerotic scores evaluated the severity of the damage and were in a range from 0 to 2+ (0, normal glomerulus; 1+, Intervention of FSGS by IL-10 gene therapy Y-K Choi et al sclerosis involving less than 50% of a glomerular tuft area; 2+, sclerosis involving more than 50% of a glomerular tuft area). The glomerular sclerotic index was calculated as follows: sclerotic index¼ [(n0 Â 0)+(n1 Â 1)+(n2 Â 2)]/total glomeruli counted. A minimum of 50 glomeruli was randomly assessed to determine the sclerotic index for each animal.
Quantitative RT-PCR
Total RNA was purified from the kidney using the TriPure TM (Roche Molecular Biochemicals) reagent 4 weeks after Ad:LacZ or Ad:hIL-10 transduction. Transcript levels of both TGF-b1 and GAPDH were measured using a real-time PCR machine (MJ Research, San Francisco, CA, USA). Primer sequences were as follows: TGF-b1: 5 0 -GAC TAC TAT GCT AAA GAG GTC ACC-3 0 (sense) and 5 0 -CTG ATC CCG TTG ATT TCC ACG TGG-3 0 (antisense); GAPDH: 5 0 -CCA GTA TGA CTC CAC TCA CGG-3 0 (sense), and 5 0 -CAA CCT GGT CCT CAG TGT AGC C-3 0 (antisense). Results were expressed as the ratio between amplified DNA fragments of TGF-b1 and GAPDH mRNA.
Immunostaining for TGF-b
Cryostat sections were incubated in a sequence, in Bouin's fixative for 5 min, in acetone at 41C for 10 min, in methanol at À201C for 15 min, in 2% paraformaldehyde for 2 min, in 4% paraformaldehyde for 4 min, and in 70% ethanol for 10 min. The sections were rehydrated with graded ethanol, and were washed with PBS and incubated for 30 min with methanol containing 0.3% H 2 O 2 to remove endogenous peroxidase activity. Blocking was done in PBS containing 10% FBS for 1 h and incubated overnight with a rabbit anti-TGF-b1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in PBS containing 0.5% BSA and 2% FCS at 41C. The tissues were incubated with anti-rabbit HRP conjugates (Sigma) for 1 h at room temperature. The tissues were then incubated with diamine benzidine (Sigma) for 5 min, dehydrated and mounted with synthetic mountant.
Statistical analysis
Results are expressed as means7standard deviation (s.d.). Statistical significance was determined using Student's t-test. Po0.05 was considered significant.
